Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of everolimus plus sorafenib in advanced hepatocellular carcinoma
NL-OMON24345Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus and sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Pharmacokinetic exposure and 2 more. Started Jan 2009; status: recruiting.
02
Drugs
everolimussorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON24345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24345.